nephrologylinx Medical News about Treatment of Hypokalemia in Peritoneal Dialysis Patients

Click the title below to leave the MDLinx Network and go to the Journal's Website

Spironolactone is not Effective for the Treatment of Hypokalemia in Peritoneal Dialysis Patients
Hong Kong Journal of Nephrology, 05/09/08

Email This Article

Save in My Library

Free Abstract

Kwok J S-S et al. - Spironolactone is not effective in the treatment of hypokalemia in stable CAPD patients, but the agent is well tolerated, at least in CAPD patients with little residual renal function. Future studies are warranted to determine the therapeutic role of spironolactone in CAPD patients with concomitant congestive heart failure or cardiovascular disease.

--- DIALYSIS TOP ARTICLES ---

Receive free subspecialty "5-minute updates" via email

Acid-base disturbances in the intensive care unit: Current issues and the use of continuous renal replacement therapy as a customized treatment tool
The International Journal of Artificial Organs, 04/15/08

Uremic pruritus in chronic hemodialysis patients
Journal of Nephrology, 04/25/08

Effect of Clopidogrel on Early Failure of Arteriovenous Fistulas for Hemodialysis
JAMA, 05/15/08

...All of Dialysis

--- FLUIDS AND ELECTROLYTES TOP ARTICLES ---

Receive free subspecialty "5-minute updates" via email

Hypernatraemia in critically ill patients: too little water and too much salt
Nephrology Dialysis Transplantation, 04/24/08

Hyperphosphatemia of chronic kidney disease
Kidney International, 05/01/08

Niacin and Related Compounds for Treating Hyperphosphatemia in Dialysis Patients
Seminars in Dialysis, 04/17/08

...All of Fluids and Electrolytes

Sponsor

--- PHARMACOLOGY/KINETICS TOP ARTICLES ---

Receive free subspecialty "5-minute updates" via email

Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Renal Failure, 03/26/08

Long-term follow-up of patients with IgA nephropathy treated with prednisolone and cyclophosphamide therapy
Clinical and Experimental Nephrology, 05/07/08

Renoprotective effects of angiotensin II receptor blocker, candesartan cilexetil, in patients with stage 4–5 chronic kidney disease
Clinical and Experimental Nephrology, 05/09/08

...All of Pharmacology/kinetics